Ignite Creation Date:
2024-05-06 @ 7:32 PM
Last Modification Date:
2024-10-26 @ 3:08 PM
Study NCT ID:
NCT06041841
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-11-02
First Post:
2023-09-11
Brief Title:
A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity
Sponsor:
LG Chem
Organization:
LG Chem
Study Overview
Official Title:
A Phase 2 Single-arm Open-label Study to Assess Efficacy and Safety of LB54640 in Patients With Obesity Due to POMC PCSK1 or LEPR Deficiency
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study was to assess the efficacy of LB54640 in participants with rare genetic disorders of obesity
Detailed Description:
Patients with obesity due to POMC PCSK1 or LEPR deficiency will be enrolled to receive LB54640 by oral administration for 16 weeks After 16 weeks of treatment the participant may enter a long term extension phase and receive treatment for up to 1 year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None